SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Moderna Outlines Growth Plans at Analyst Day

Moderna highlighted intismeran and cancer antigen therapies as opportunities for its oncology franchise, and discussed commercial and manufacturing readiness for intismeran after positive Phase 3 results in adjuvant melanoma.

MRNA

Related stories